Skip to main content
Clinical Trials/jRCT2031230082
jRCT2031230082Active, not recruitingNot Applicable

A Phase 1 Study of S-892216 in Healthy Adults (COVID-19)

Shionogi & Co., Ltd.0 sites347 target enrollmentStarted: May 1, 2023Last updated:

Trial Snapshot

Phase
Not Applicable
Status
Active, not recruiting
Enrollment
347

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional
Allocation
Randomized Controlled Trial
Intervention Model
Parallel Assignment
Primary Purpose
Treatment Purpose
Masking
Double Blind

Eligibility Criteria

Ages
18age old over to No limit (—)
Sex
All

Inclusion Criteria

  • Common in all parts
  • Apparently healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs, and 12-lead ECG at screening and on admission. Or, determined to be eligible for participation by the investigator or subinvestigator in consideration of the safety in case for participants with clinical laboratory test results beyond the upper limit or below the lower limit of the reference range of the study site.
  • Male and female
  • Capable of giving signed informed consent as described in this protocol which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
  • Only for part 1, 2, and 4
  • Participant must be 18 to 55 years of age inclusive, at the time of signing the ICF.
  • A person with Japanese parents.
  • Body Mass Index (BMI) >= 18.5 and <= 30.
  • Only for Part 3
  • Participant must be 18 to 55 years of age inclusive, at the time of signing the ICF.
  • In Cohort H and J, a person with Japanese parents.
  • In Cohort K, a healthy adult White with White parents (regardless of nationality of the parents), who lives in Japan. Must possess Japanese citizenship, a special permanent resident certificate, or a residence card.
  • Body Mass Index (BMI) >= 18.5 and <= 30.
  • Only for Part 5
  • Participant must be 65 years of age and older at the time of signing the ICF.
  • A person with Japanese parents.
  • Body Mass Index (BMI) >= 18.5 and <= 30.
  • Body weight >= 40 kg.
  • Only for Part 6, 7, and 8
  • Participants must be 18 to 55 years of age inclusive, at the time of signing the ICF.
  • A person with Japanese parents.
  • Body Mass Index (BMI) >= 18.5 and <=30.
  • (Only for Part 6 and 7) Body weight >= 70 kg.
  • Only for Part 9
  • Participants must be 18 to 45 years of age inclusive, at the time of signing the ICF.
  • A person with Japanese parents.
  • Body Mass Index (BMI) >= 18.5 and <= 30.0, and body weight >= 40 kg.

Exclusion Criteria

  • Common in all parts
  • History of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, hematological, or neurological disorders that may significantly alter the absorption, metabolism, or elimination of drugs; determined to constitute a risk when administering the study intervention or to interfere with the interpretation of data.
  • In C-SSRS examined at screeing or on admission, 'Yes' to questions regarding suicidal ideation 1 to 5, or to questions regarding unintended self-injury behavior out of suicidal behavior, or judged as having risks for suicide in the opinion of the investigator (Part 1-5).
  • At screeing or on admission, The total score of 10 points or more in PHQ-9 (Part 1-5).

Investigators

Similar Trials